NIM
SNDX icon

NEOS Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

NEOS Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-101,553
Closed -$2.13M – 646
2025
Q4 		$2.13M Sell
101,553
-8,513
-8% -$149K 0.01% 467
2025
Q3 		$1.69M Buy
110,066
+23,765
+28% +$311K 0.01% 460
2025
Q2 		$808K Buy
86,301
+65,132
+308% +$717K 0.01% 490
2025
Q1 		$260K Buy
+21,169
New +$299K ﹤0.01% 564

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

NEOS Investment Management's SNDX Position: Q1 2026 in Review

NEOS Investment Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 101,553 shares — an estimated $2.13M sold.

NEOS Investment Management first reported a position in SNDX in Q1 2025 and held it in 4 quarters. The position peaked at $2.13M in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • NEOS Investment Management reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 101,553 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.13M.
  • NEOS Investment Management first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • NEOS Investment Management's Syndax Pharmaceuticals position peaked at $2.13M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.